



Make an Appointment

In the News Battile Of Entrope 18. Treatment

Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership

History

Equality, diversity & inclusion

Annual report

Give to MSK

Infection by antibiotic-resistant bacteria is a dangerous complication of broadspectrum antibiotic therapy. Treatment with antibiotics impairs natural immune defenses in the intestines, allowing antibiotic-resistant microbes to flourish. Now Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to vancomycin-resistant Enterococcus (VRE), a potentially harmful antibiotic-resistant bacterium.



Eric G. Pamer

Enterococcus is harmless when it remains in the intestines. However, it can cause life-threatening infections if it traverses the intestinal lining and invades the bloodstream. Enterococcus strains are increasingly resistant to antibiotics, including vancomycin.

Fortunately the intestines are equipped with an innate immune defense, explained Memorial Sloan Kettering immunologist Eric G. Pamer, senior author of the study, which was published in October in Nature. Resident bacteria known as commensals are involved in triggering this defense system. When molecules on their surfaces bind to receptors on the cells of the intestinal lining, the cells start pumping out bacteria-killing proteins, including RegIII fngamma.

Dr. Pamer's team found that antibiotics destroy this defense system by killing commensal bacteria and dampening RegIII fngamma production. Without RegIII fngamma, VRE proliferates in the intestines and invades the bloodstream. "These antibiotics don't just make VRE a predominant organism in the gut," explained Dr. Pamer. "They actually weaken the intestine's immune defenses."

In mice, Dr. Pamer's group restored RegIII fingamma production in antibiotic-treated, VRE-infected animals by adding lipopolysaccharide (LPS), a component of the commensal bacterial membranes, to their drinking water. LPS-treated mice had significantly lower levels of intestinal VRE compared with untreated mice. "By reactivating the host defense systems, we can restore the intestine's natural ability to fight pathogens," explained Dr. Pamer.

Antibiotic-mediated compromise of the intestine's innate defenses is one further reason antibiotics should be used judiciously, observed Dr. Pamer. Therapies that increase RegIII fngamma have the potential to protect individuals taking broad-spectrum antibiotics, and while LPS has toxic properties, it may be useful in certain clinical situations.

Co-authors from Memorial Sloan Kettering on this study were Katharina Brandl, <u>George Plitas</u>, Coralia N. Mihu, Carles Ubeda, Ting Jia, <u>Martin Fleisher</u>, and Ronald P. DeMatteo.

- Connect		
Contact us		
<u>Locations</u>		
APPOINTMENTS		
800-525-2225 —		
- About MSK		
About us		
<u>Careers</u>		
Giving.		
- Cancer Care		
Adult cancer types		
Child & teen cancer types		
Integrative medicine		
Nutrition & cancer		
Find a doctor		
- Research & Education		
Sloan Kettering Institute		
Gerstner Sloan Kettering Graduate School ■		
Graduate medical education		
MSK Library		

Communication preferences

Cookie preferences

Legal disclaimer

Accessibility statement

Privacy policy

Price transparency

Public notices

© 2024 Memorial Sloan Kettering Cancer Center